recombin
protein
contain
one
heptadrepeat
segment
one
segment
shown
fold
thermal
stabl
sixhelix
bundl
repres
fusogen
core
studi
use
fusogen
core
scaffold
design
fusion
inhibitori
protein
link
anoth
c
terminu
addit
n
terminu
recombin
protein
could
abundantli
solubl
express
easili
purifi
exhibit
high
stabil
potent
inhibitori
activ
fusion
ic
valu
nm
respect
suggest
ration
design
protein
develop
novel
therapeut
fusion
entri
human
immunodefici
viru
type
mediat
envelop
env
glycoprotein
env
protein
synthes
precursor
polypeptid
proteolyt
cleav
two
noncoval
attach
protein
respons
bind
cellular
receptor
certain
chemokin
coreceptor
possess
membran
fusion
activ
n
terminu
contain
hydrophob
fusion
peptid
follow
two
wellconserv
heptadrepeat
region
play
crucial
role
membran
fusion
upon
bind
cellular
receptor
undergo
seri
conform
chang
convert
nativ
nonfusogen
conform
fusogen
conform
fusogen
core
trimerofhairpin
structur
sixhelix
bundl
three
helic
pack
central
trimer
coiledcoil
form
three
helic
format
trimerofhairpin
bring
viral
cellular
membran
close
proxim
necessari
membran
fusion
occur
fusion
process
nativ
convert
transient
popul
prehairpin
intermedi
prior
format
fusogen
trimerofhairpin
structur
fusion
peptid
insert
target
cell
membran
transient
access
inhibitori
compound
peptid
deriv
region
inhibit
membran
fusion
bind
prehairpin
intermedi
block
proper
format
trimerofhairpin
thu
prevent
membran
fusion
recombin
protein
contain
segment
separ
short
hydrophil
sixresidu
linker
produc
shown
fold
thermal
stabl
sixhelix
bundl
base
design
two
protein
one
peptid
link
c
terminu
one
peptid
link
n
terminu
rational
design
three
heptadrepeat
two
one
one
two
link
flexibl
linker
protein
associ
form
hairpin
structur
consequ
three
molecul
protein
form
stabl
sixhelix
bundl
three
free
heptadrepeat
expos
fig
free
bind
counterpart
region
viral
therebi
block
membran
fusion
show
well
express
solubl
protein
could
easili
purifi
two
protein
inhibit
membran
fusion
nanomolar
concentr
gene
construct
gene
encod
viral
fragment
residu
residu
fragment
residu
residu
amplifi
pcr
express
vector
consist
two
segment
one
segment
altern
link
short
peptid
sequenc
consist
two
segment
one
segment
sequenc
c
n
linker
linker
gssgg
n
c
linker
linker
ggsgg
gene
encod
protein
subclon
escherichia
coli
express
vector
pharmacia
two
restrict
enzym
site
ecori
xhoi
stop
codon
introduc
xhoi
site
clone
strategi
yield
glutathion
stransferas
gst
fusion
protein
design
respect
subclon
bamhixhoi
site
yield
protein
ntermin
histag
thrombin
enterokinas
cleavag
site
name
respect
protein
express
purif
protein
express
e
coli
strain
purifi
glutathionesepharos
affin
column
accord
method
describ
earlier
appli
nichel
sepharos
affin
column
cd
spectroscopi
cd
spectra
perform
jasco
spectrophotomet
protein
pb
wavelength
spectra
record
use
cm
pathlength
cuvett
protein
concentr
use
lgml
gst
pulldown
assay
excess
classifi
bacterium
supernat
mix
respect
mixtur
incub
h
room
temperatur
glutathionesepharos
affin
gel
ad
gel
protein
mixtur
incub
gentl
agit
room
temperatur
min
centrifug
min
supernat
remov
gel
adsorb
fusion
protein
complex
load
column
wash
volum
pb
elut
segment
also
indic
b
contain
two
segment
one
segment
altern
link
short
glyser
peptid
sequenc
consist
two
segment
one
segment
sequenc
construct
peptid
respect
linker
gssgg
linker
ggsgg
c
schemat
model
trimer
left
right
assembl
sixhelix
bundl
free
reduc
lglutathion
elut
sampl
analyz
sdspage
inhibit
env
glycoproteinmedi
viruscel
fusion
inhibit
viruscel
fusion
determin
use
recombin
luciferas
report
assay
viru
pseudotyp
env
glycoprotein
produc
cotransfect
cell
genom
contain
frameshift
mutat
env
luciferas
gene
replac
nef
r
cellular
debri
remov
lowspe
centrifug
supernat
contain
pseudoviru
particl
mix
serial
dilut
protein
test
virusprotein
mixtur
transfer
plate
seed
cell
three
hour
later
medium
replac
incub
day
cell
harvest
lyse
lysi
buffer
follow
addit
luciferas
substrat
luciferas
activ
measur
luminomet
ic
valu
calcul
fit
titrat
data
langmuir
function
luciferas
activ
cic
c
concentr
protein
inhibitor
express
purifi
solubl
protein
produc
use
recombin
e
coli
express
system
abl
provid
protein
product
larg
quantiti
low
cost
two
design
protein
express
gst
fusion
protein
solubl
readili
elut
glutathionesepharos
column
normal
elut
buffer
mm
reduc
glutathion
mm
trishcl
ph
moreov
two
gst
fusion
protein
could
easili
cleav
proteas
fig
b
everi
liter
cell
could
yield
mg
respect
suggest
solubl
recombin
protein
effici
express
purifi
larg
quantiti
low
cost
purifi
analyz
gel
filtrat
estim
molecular
weight
assembl
charact
elut
peak
protein
peak
posit
correspond
kda
fig
sdspage
show
major
band
molecular
weight
kda
inset
fig
agreement
calcul
molecular
weight
kda
respect
data
suggest
could
form
trimer
structur
ie
sixhelix
bundl
pb
howev
unlik
sixhelix
bundl
form
form
expect
express
three
unassoci
helic
fig
biophys
properti
individu
protein
concern
test
cd
spectrometri
describ
materi
method
cd
spectrum
exhibit
doubl
minima
nm
indic
show
salient
ahelix
charact
unord
fig
strong
tendenc
aggreg
solubl
liabl
precipit
pb
partial
solubl
clarifi
bacterium
supernat
could
acquir
purifi
analyz
structur
howev
base
studi
partial
ahelix
accordingli
two
design
protein
stabl
singl
bound
bind
bound
pull
fig
c
impli
gst
well
fusion
partner
extra
amino
acid
affect
bind
activ
result
suggest
analog
monom
respect
might
bind
counterpart
region
viral
block
fusion
viral
target
cell
membran
potent
inhibit
env
glycoproteinmedi
viruscel
fusion
found
antivir
activ
fig
gst
alon
could
inhibit
viruscel
fusion
mediat
env
glycoprotein
even
lm
ic
valu
assay
nm
respect
monom
also
test
inhibitori
activ
env
glycoproteinmedi
viruscel
fusion
assay
ic
valu
nm
lower
possibl
fold
good
bind
site
expos
well
sinc
strong
tendenc
aggreg
could
acquir
purifi
inhibitori
activ
test
peptid
deriv
region
potent
inhibitor
entri
ic
valu
low
nanomolar
rang
one
peptid
brand
name
fuzeon
gener
name
enfuvirtid
approv
us
food
drug
administr
fda
european
commiss
treatment
infect
adult
children
fail
respond
current
antiretrovir
drug
inhibitori
activ
provid
compel
evid
prehairpin
intermedi
use
target
therapi
howev
although
effect
block
vitro
infect
nanomolar
level
larg
amount
peptid
drug
mgday
requir
maintain
vivo
efficaci
human
therefor
treatment
price
per
patient
per
year
unit
state
europ
respect
one
major
limit
difficulti
peptid
synthesi
result
high
cost
product
insuffici
suppli
peptid
deriv
region
thought
either
bind
region
prehairpin
intermedi
hinder
format
intern
trimer
coiledcoil
possess
activ
three
order
magnitud
lower
peptid
presum
aggreg
inabl
form
trimer
coiledcoil
absenc
peptid
therefor
necessari
design
new
class
molecul
target
viral
potent
activ
high
stabil
low
cost
product
studi
show
construct
coval
attach
peptid
residu
residu
short
flexibl
linker
could
form
highli
thermost
ahel
trimer
repres
smallest
stabl
fold
core
lu
also
show
linker
stabil
fold
core
entrop
reason
without
perturb
structur
base
made
use
fusogen
core
scaffold
link
anoth
c
terminu
addit
n
terminu
design
two
protein
denot
respect
construct
residu
peptid
extend
six
residu
ctermin
sequenc
segment
select
segment
segment
mainli
peptid
inhibit
entri
lowest
ic
valu
nm
solventexpos
trimer
coiledcoil
stabil
directli
link
c
terminu
thermost
core
fragment
compris
sixhelix
bundl
flexibl
linker
highli
potent
inhibitor
env
glycoproteinmedi
cell
fusion
ic
valu
nm
sustain
peptid
coiledcoil
conform
strikingli
dramat
increas
antivir
potenc
correspond
peptid
tendenc
aggreg
inhibitori
activ
compar
five
six
helic
constitut
trimerofhairpin
link
coval
singl
polypeptid
lack
third
segment
vacanc
creat
highaffin
bind
site
peptid
potent
broadspectrum
inhibitor
membran
fusion
ic
valu
low
nanomolar
rang
howev
express
e
coli
inclus
bodi
result
difficulti
purifi
construct
graft
one
n
terminu
core
inhibit
membran
fusion
nanomolar
concentr
also
extract
inclus
bodi
synthes
high
cost
compar
inhibitor
target
region
prehairpin
intermedi
express
e
coli
solubl
protein
easili
purifi
hand
inhibitori
activ
test
hypothesi
weak
inhibit
peptid
result
tendenc
aggreg
absenc
peptid
three
peptid
stabil
link
sixhelix
bundl
also
highli
potent
inhibitor
env
glycoproteinmedi
cell
fusion
inhibitori
activ
compar
stabil
improv
product
low
cost
design
alreadi
appli
sarscov
inhibit
hivsar
pseudotyp
virus
entri
micromolar
rang
word
design
protein
easili
express
purifi
product
low
cost
exhibit
typic
ahel
structur
potenti
use
therapeut
agent
manner
analog
peptid
deriv
